SuperworthAspire Biopharma EPS ASBP
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$1.22
- Fiscal year 2024
- −$1404.00
- −936% on the year before
Aspire Biopharma's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$1.22.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$1404.00 | −936% |
| FY2023 | $168.00 | −58% |
| FY2022 | $396.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.22 | n/a | n/a | |
| Q1 FY26 | −$20.57 | n/a | n/a | |
| Q3 FY25 | −$48.00 | n/a | −$1476.69 | |
| Q2 FY25 | −$48.19 | n/a | −$1440.69 | |
| Q1 FY25 | −$0.50 | n/a | −$1392.50 | |
| Q4 FY24 | −$1380.00 | n/a | −$1404.00 | |
| Q3 FY24 | −$12.00 | n/a | −$48.00 | |
| Q2 FY24 | $0.00 | −100% | −$48.00 | |
| Q1 FY24 | −$12.00 | −113% | $60.00 | |
| Q4 FY23 | −$24.00 | −106% | $168.00 | |
| Q3 FY23 | −$12.00 | −133% | $564.00 | |
| Q2 FY23 | $108.00 | n/a | $612.00 |
Against its peers
Companies in Drug Manufacturers - General nearest Aspire Biopharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ASBPAspire Biopharma | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Aspire Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.